Atypical Presentations of GERD in Older Patients: Strategies for Early Identification and Treatment to Limit Disease Progression

Sponsored by Princeton CME

Target Audience

This activity is designed for clinical and managed care pharmacists.

Learning Objectives

After completing this activity, participants should be able to:

Outline the atypical gastroesophageal reflux disease (GERD) presentations frequently seen in older patient populations
Identify the clinical and economic burden associated with GERD disease progression
Articulate the benefits, limitations, and safety profiles of available pharmacologic agents
Institute formulary models that promote optimal medication management to limit the clinical and economic burden of GERD and GERD complications

Credit Eligibility

To be eligible for documentation of credit, all participants must participate in the full educational activity, complete the 10-question post-test with a score of 70% or better, and complete the evaluation form. Participants who successfully complete the post-test and evaluation form online may immediately print their documentation of credit.

Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.

Release Date: March 28, 2008
Expiration Date: March 28, 2009

Estimated time to complete: 1 hour

There is no fee associated with this activity.

Lecture Components

The presentation slides, post-test, and evaluation form are available as a click through via the menu at the top of each page of this educational activity.

CPE Accreditation

Princeton CME is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education (ACPE Provider #452) and complies with the Criteria for Quality and Interpretive Guidelines. This activity is approved for 1 contact hour (0.1 CEU) of continuing pharmacy education (UPN 452-000-08-005-H01-P).

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity sponsored or cosponsored by Princeton CME may contact the Assistant Director of Continuing Education in writing. The Assistant Director of Education will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Director of Continuing Education may be made for a second level of review.

Grant Support

Supported by an educational grant from TAP Pharmaceutical Products, Inc.

Participating Faculty

Faculty
Main Presenter

John E. Pandolfino, MD, MSCI
Associate Professor of Medicine
Feinberg School of Medicine
Northwestern University
Chicago, Illinois

Case Presenter

John W. Devlin, PharmD, BCPS, FCCM, FCCP
Associate Professor
Northeastern University School of Pharmacy
Adjunct Associate Professor
Tufts University School of Medicine
Boston, Massachusetts

Independent Clinical Reviewer

Frank Friedenberg, MD
Associate Professor, Medicine
Temple University School of Medicine
Philadelphia, Pennsylvania

Financial Disclosure and Conflicts of Interest
According to the disclosure policy of Princeton CME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of Princeton CME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are viewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty has reported the following:

Dr. Pandolfino: Research Funding, Principal Investigator—AstraZeneca (funds paid to Northwestern University); Consultant—AstraZeneca, Medtronic, Santarus; Speaker—AstraZeneca, Medtronic, Santarus.

Dr. Devlin: Research Funding, Principal Investigator—AstraZeneca, Hospira, TAP Pharmaceutical Products Inc. (funds paid to Northeastern University); Consultant—Hospira, TAP Pharmaceutical Products Inc., The Medicines Company; Speaker—Hospira, TAP Pharmaceutical Products Inc.

Dr. Friedenberg: Research Funding, Principal Investigator—AstraZeneca, Viro Pharma, Inc. (Funds Paid to Temple University School of Medicine); Consultant—Viro Pharma, Inc.; Speaker—Viro Pharma, Inc.

Planning committee Randy Robbin and John Savage, Princeton CME; Rosemary Hodgson and William Kormos, Princeton Media Communications have disclosed that they have no significant financial relationships.

Princeton CME requires faculty to inform participants whenever off-label/unapproved uses of drugs or devices are discussed in their presentations.

The faculty has disclosed that no off-label/unapproved uses of drugs or devices will be discussed.